Edesa Biotech Inc EDSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EDSA is a good fit for your portfolio.
News
-
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
-
Edesa Biotech to Participate in Upcoming Investor Conferences
-
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
-
Edesa Biotech to Participate in Barclays Global Healthcare Conference
-
Edesa Biotech to Participate in Upcoming Dermatology Meetings
-
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Trading Information
- Previous Close Price
- $4.49
- Day Range
- $4.58–4.58
- 52-Week Range
- $2.50–8.27
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $14.73 Mil
- Volume/Avg
- 590 / 11,747
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.edesabiotech.com
Valuation
|
Metric
|
EDSA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.41 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
EDSA
Financial Strength
|
Metric
|
EDSA
|
|---|---|
Quick Ratio | 2.52 |
Current Ratio | 2.73 |
Interest Coverage | — |
Quick Ratio
EDSA
Profitability
|
Metric
|
EDSA
|
|---|---|
Return on Assets (Normalized) | −71.24% |
Return on Equity (Normalized) | −86.32% |
Return on Invested Capital (Normalized) | −87.86% |
Return on Assets
EDSA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Glybzblpdm | Jrc | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pzpmhjwtv | Bgsgn | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ytkmrqyh | Pwpjhc | $99.6 Bil | |
MRNA
| Moderna Inc | Clwlmty | Pqwb | $42.7 Bil | |
ARGX
| argenx SE ADR | Lqnkwzyw | Lvtp | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Vyxnslyz | Gzd | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ylfbzgjxm | Pvvnnbh | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Whfkrznrl | Qkhff | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cdhhwjmw | Qhcnvx | $12.7 Bil | |
INCY
| Incyte Corp | Ljctgcv | Dbbcnq | $11.9 Bil |